In the pharmaceutical and biotechnological fields, artificial intelligence is no longer a future prospect but a structural element of research, development, and manufacturing.

For a Contract Development and Manufacturing Organization (CDMO), its value lies in the ability to extract actionable knowledge from experimental and production data, accelerating the identification of critical correlations between process parameters, biological performance, and product quality.

Through machine learning and deep learning models, it is now possible to predict the evolution of fermentation processes, simulate complex operating conditions, and optimize purification or formulation protocols.

In a context governed by GMP standards and rigorous validation and traceability requirements, this analytical intelligence becomes a strategic resource to ensure process consistency, production stability, and continuous innovation.

AI and R&D: data that accelerate discovery

In the research and development phase, AI has already demonstrated its ability to significantly shorten the time needed to identify, test, and optimize new biopharmaceutical candidates.

Machine learning and deep learning algorithms are trained on extensive databases containing millions of molecular combinations, fermentation parameters, or protein expression profiles, learning to recognize patterns associated with compound efficacy or stability.

Key areas of application include:

  • Drug design and molecular optimization, supported by generative networks capable of proposing new chemical structures with targeted properties.
  • In silico screening, which reduces the number of required in vitro experiments, saving both time and resources.
  • Multi-omic analysis, where AI integrates genomic, proteomic, and metabolomic data to better understand biological mechanisms and improve therapeutic target selection.

 

For CDMOs, this translates into faster, more focused, and reproducible development projects, where each new formulation can be optimized using validated predictive models.

AI in manufacturing: precision, efficiency, and control

Artificial intelligence finds one of its most tangible applications in biotechnological manufacturing, where the ability to monitor, analyze, and correct processes in real time is a decisive competitive advantage.

Main application areas include:

  • Predictive maintenance, through algorithms that continuously analyze sensor data to anticipate deviations or equipment failures, minimizing downtime.
  • Quality control powered by computer vision, where high-resolution cameras combined with convolutional neural networks (CNNs) detect defects or contamination in products and packaging.
  • Process parameter optimization, using reinforcement learning models that learn from each batch outcome to progressively improve the efficiency of fermentation, purification, or aseptic filling stages.
  • Production data analysis (Process Analytical Technology, PAT), allowing AI to correlate in-process data with final product characteristics and support a continuous improvement approach in line with ICH Q8–Q10 guidelines.

 

In essence, AI transforms routine data into operational intelligence, making production not only more automated but also smarter and more resilient.

Data, ethics, and regulation: the role of the EU AI Act

The integration of artificial intelligence into CDMO processes must comply with the EU AI Act, which classifies AI systems according to four risk levels and introduces strict requirements for high-impact applications, such as those used in pharmaceutical and biotechnological environments.

Key obligations include:

  • Implementation of a risk management system and comprehensive technical documentation for the AI model.
  • Human-in-the-loop supervision, preventing uncontrolled automated decisions.
  • Transparency and explainability, ensuring every system can justify its outcomes and maintain full data traceability.
  • Cybersecurity and data protection, aligned with GDPR and GxP

 

For CDMOs, the integration of artificial intelligence must be guided by robust governance frameworks and aligned with regulatory standards such as the EU AI Act.

Adhering to principles of transparency, traceability, and human oversight is essential to ensure that innovation develops within a framework of ethics, safety, and accountability.
Only a conscious and well-regulated approach to digital technologies can enable a truly responsible evolution of biotechnological processes.

The synergy between AI and human expertise

Despite its analytical power, artificial intelligence reaches its true potential when combined with human experience.

AI can analyze, suggest, and predict — but it is scientists, technologists, and process experts who interpret data, validate insights, and translate them into operational decisions.

The most advanced CDMOs are not merely adopting digital tools: they are redefining their operational models, fostering a data-driven culture based on continuous learning, interdisciplinary collaboration, and adaptability.

This evolution involves every level of the organization — from microbiology labs to production departments, quality assurance, and regulatory teams.

Towards predictive biomanufacturing

Artificial intelligence offers CDMOs new opportunities to move towards predictive, flexible, and data-driven manufacturing models capable of improving process awareness and responsiveness.
Its value lies not in replacing human expertise, but in supporting it — fostering more informed decision-making and continuous improvement.

In this evolving landscape, companies in the biotech field are called to combine scientific rigor with ethical responsibility, adopting a thoughtful approach to technological innovation that prioritizes quality, safety, and integrity at every stage of development.